Research Analysts Set Expectations for Zura Bio Q3 Earnings

Zura Bio Limited (NASDAQ:ZURA) – Equities research analysts at HC Wainwright increased their Q3 2025 earnings estimates for Zura Bio in a research report issued to clients and investors on Monday, November 11th. HC Wainwright analyst M. Kapoor now expects that the company will earn ($0.23) per share for the quarter, up from their prior forecast of ($0.24). HC Wainwright has a “Neutral” rating and a $5.00 price objective on the stock. The consensus estimate for Zura Bio’s current full-year earnings is ($0.61) per share.

Zura Bio (NASDAQ:ZURA) last announced its earnings results on Thursday, November 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12).

A number of other analysts have also recently issued reports on the company. Cantor Fitzgerald restated an “overweight” rating on shares of Zura Bio in a research report on Friday, October 18th. Leerink Partners assumed coverage on shares of Zura Bio in a report on Monday, November 4th. They issued an “outperform” rating and a $15.00 price target on the stock. Leerink Partnrs upgraded shares of Zura Bio to a “strong-buy” rating in a research note on Monday, November 4th. Piper Sandler reiterated an “overweight” rating and set a $26.00 target price on shares of Zura Bio in a research report on Thursday, September 19th. Finally, Chardan Capital cut their price target on shares of Zura Bio from $14.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, November 8th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Zura Bio currently has an average rating of “Buy” and an average target price of $15.80.

Zura Bio Trading Down 17.8 %

NASDAQ ZURA opened at $3.60 on Wednesday. Zura Bio has a twelve month low of $2.00 and a twelve month high of $6.35. The firm has a 50-day simple moving average of $4.21 and a 200 day simple moving average of $4.12.

Hedge Funds Weigh In On Zura Bio

Large investors have recently modified their holdings of the stock. Affinity Asset Advisors LLC bought a new position in Zura Bio in the 1st quarter worth approximately $1,157,000. Bank of New York Mellon Corp increased its stake in shares of Zura Bio by 15.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 47,109 shares of the company’s stock valued at $165,000 after buying an additional 6,412 shares during the period. Renaissance Technologies LLC raised its position in shares of Zura Bio by 51.3% during the second quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock worth $61,000 after acquiring an additional 5,900 shares during the last quarter. Great Point Partners LLC lifted its stake in shares of Zura Bio by 68.3% during the second quarter. Great Point Partners LLC now owns 4,642,241 shares of the company’s stock valued at $16,248,000 after acquiring an additional 1,884,501 shares during the period. Finally, Armistice Capital LLC boosted its holdings in Zura Bio by 53.2% in the second quarter. Armistice Capital LLC now owns 2,524,000 shares of the company’s stock valued at $8,834,000 after acquiring an additional 876,000 shares during the last quarter. 61.14% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Someit Sidhu sold 51,728 shares of Zura Bio stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $3.87, for a total value of $200,187.36. Following the completion of the transaction, the director now directly owns 2,085,418 shares of the company’s stock, valued at $8,070,567.66. The trade was a 2.42 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 22.10% of the company’s stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.